Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs.

Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S.

Hematol Rep. 2018 Mar 29;10(1):7523. doi: 10.4081/hr.2018.7523. eCollection 2018 Mar 2.

2.

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Tadmor T, Bari A, Marcheselli L, Sacchi S, Aviv A, Baldini L, Gobbi PG, Pozzi S, Ferri P, Cox MC, Cascavilla N, Iannitto E, Federico M, Polliack A.

Mayo Clin Proc. 2015 Jun;90(6):756-64. doi: 10.1016/j.mayocp.2015.03.025.

3.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.

Iannitto E, Luminari S, Tripodo C, Mancuso S, Cesaretti M, Marcheselli L, Merli F, Stelitano C, Carella AM, Fragasso A, Montechiarello E, Ricciuti G, Pulsoni A, Paulli M, Franco V, Federico M.

Leuk Lymphoma. 2015;56(12):3281-7. doi: 10.3109/10428194.2015.1029925. Epub 2015 Jul 18.

PMID:
25791121
4.

"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".

Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N.

Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23.

PMID:
25636354
5.

Two cases of q-Fever in hairy cell leukemia.

Ammatuna E, Iannitto E, Tick LW, Arents NL, Kuijper PH, Nijziel MR.

Case Rep Hematol. 2014;2014:863932. doi: 10.1155/2014/863932. Epub 2014 Aug 12.

6.

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma.

Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, Pucillo C, Colombo MP, Sangaletti S, Tripodo C.

Blood. 2014 Mar 20;123(12):1836-49. doi: 10.1182/blood-2013-04-497271. Epub 2014 Jan 22.

7.

Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

Molica S, Brugiatelli M, Morabito F, Ferrara F, Iannitto E, Di Renzo N, Capalbo S, Musto P, Di Raimondo F.

Expert Rev Hematol. 2013 Aug;6(4):441-9. doi: 10.1586/17474086.2013.814845. Review.

PMID:
23991930
8.

Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use.

Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri AJ, Salar A, Rattotti S, Carpaneto A, Perez R, Bello JL, Hernandez M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group (SMZLSG).

Leuk Lymphoma. 2014 Apr;55(4):929-31. doi: 10.3109/10428194.2013.818143. Epub 2013 Jul 29. No abstract available.

PMID:
23799931
9.

Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.

Gentile M, Cutrona G, Fabris S, Pesce EA, Baldini L, Di Raimondo F, Musolino C, Di Tonno P, Di Renzo N, Molica S, Brugiatelli M, Ilariucci F, Zupo S, Matis S, Maura F, Vigna E, Angrilli F, Recchia AG, Quarta G, Iannitto E, Fragasso A, Musto P, Spriano M, Vincelli I, Vallisa D, Cortelezzi A, Mauro FR, Foà R, Federico M, Neri A, Ferrarini M, Morabito F.

Am J Hematol. 2013 Jul;88(7):539-44. doi: 10.1002/ajh.23448. Epub 2013 Jun 12.

10.

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E.

Ann Oncol. 2013 Apr;24(4):857-77. doi: 10.1093/annonc/mds643. Epub 2013 Feb 20.

11.

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, Pinto A.

Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20.

PMID:
23167437
12.

Viral sequence analysis of occult HBV infection and its reactivation in immunosuppressed patients.

Ferraro D, Pizzillo P, Urone N, Iannitto E, Craxi A, Di Stefano R.

J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):457-65.

PMID:
23034265
13.

Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases.

Montalbán C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri A, Salar A, Rattotti S, Carpaneto A, Pérez Fernández R, Bello JL, Hernández M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group.

Br J Haematol. 2012 Oct;159(2):164-71. doi: 10.1111/bjh.12011. Epub 2012 Aug 24. Erratum in: Br J Haematol. 2013 Sep;162(6):864. Iannito, Emilio [corrected to Iannitto, Emilio].

PMID:
22924582
14.

Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.

Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Stelitano C, Iannitto E, Federico M.

Oncol Rep. 2012 Sep;28(3):815-20. doi: 10.3892/or.2012.1892. Epub 2012 Jun 29.

PMID:
22752083
15.

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E.

Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5. Epub 2012 Feb 15.

PMID:
22349722
16.

Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, Luminari S, Polimeno G, Federico M.

Hematol Oncol. 2012 Dec;30(4):194-9. doi: 10.1002/hon.1024. Epub 2012 Jan 23.

PMID:
22271092
17.

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A, Algara P, Santoro A, Gonzalez D, Mollejo M, Dagklis A, Gangemi F, Bosler DS, Bourikas G, Anagnostopoulos A, Tsaftaris A, Iannitto E, Ponzoni M, Felman P, Berger F, Belessi C, Ghia P, Papadaki T, Dogan A, Degano M, Matutes E, Piris MA, Oscier D, Stamatopoulos K.

Leukemia. 2012 Jul;26(7):1638-46. doi: 10.1038/leu.2012.3. Epub 2012 Jan 6.

PMID:
22222599
18.

Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.

Morabito F, Hohaus S, Mammi C, Marcheselli L, Gentile M, Merli F, Montanini A, Stelitano C, La Sala A, Scalone R, Voso MT, Luminari S, Iannitto E, Gobbi P, Federico M.

Leuk Lymphoma. 2012 Mar;53(3):406-10. doi: 10.3109/10428194.2011.623254.

PMID:
21916526
19.

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L.

Br J Haematol. 2011 May;153(3):351-7. doi: 10.1111/j.1365-2141.2011.08597.x. Epub 2011 Mar 4.

PMID:
21371003
20.

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N, Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group.

Leuk Lymphoma. 2011 May;52(5):771-5. doi: 10.3109/10428194.2011.553000. Epub 2011 Feb 8.

PMID:
21299465
21.

How I diagnose and treat splenic lymphomas.

Iannitto E, Tripodo C.

Blood. 2011 Mar 3;117(9):2585-95. doi: 10.1182/blood-2010-09-271437. Epub 2010 Nov 30.

22.

Splenic lymphangiomatosis showing rapid growth during lactation: a case report.

Patti R, Iannitto E, Di Vita G.

World J Gastroenterol. 2010 Mar 7;16(9):1155-7.

23.

Gamma-delta T-cell lymphomas.

Tripodo C, Iannitto E, Florena AM, Pucillo CE, Piccaluga PP, Franco V, Pileri SA.

Nat Rev Clin Oncol. 2009 Dec;6(12):707-17. doi: 10.1038/nrclinonc.2009.169. Epub 2009 Nov 10. Review.

PMID:
19901919
24.

Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?

Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxì A, Di Stefano R.

Liver Int. 2009 Sep;29(8):1171-7. doi: 10.1111/j.1478-3231.2009.02071.x. Epub 2009 Jul 7.

PMID:
19602139
25.

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.

Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M.

Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034.

PMID:
19406724
26.

Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.

Florena AM, Tripodo C, Di Bernardo A, Iannitto E, Guarnotta C, Porcasi R, Ingrao S, Abbadessa V, Franco V.

J Clin Pathol. 2009 Apr;62(4):331-8. doi: 10.1136/jcp.2007.054353.

PMID:
19329711
27.

Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.

Gobbi PG, Valentino F, Danova M, Morabito F, Rovati B, Mammi C, Gentile M, Merli F, Stelitano C, Luminari S, Quintana G, Iannitto E, Brugiatelli M, Federico M.

Oncol Rep. 2009 Apr;21(4):1029-35.

PMID:
19288005
28.

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.

Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A.

Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16. doi: 10.1007/s00280-009-0941-9. Epub 2009 Feb 15.

PMID:
19219604
29.

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5.

PMID:
19124807
30.

Advanced mast cell disease: an Italian Hematological Multicenter experience.

Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P.

Int J Hematol. 2008 Dec;88(5):483-488. doi: 10.1007/s12185-008-0166-4. Epub 2008 Nov 26.

PMID:
19034614
31.

CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis.

Tripodo C, Di Bernardo A, Ternullo MP, Guarnotta C, Porcasi R, Ingrao S, Gianelli U, Boveri E, Iannitto E, Franco G, Florena AM.

Haematologica. 2009 Jan;94(1):127-30. doi: 10.3324/haematol.13598. Epub 2008 Nov 23.

32.

Angioimmunoblastic T-cell lymphoma.

Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH.

Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71. doi: 10.1016/j.critrevonc.2008.06.012. Epub 2008 Aug 6. Review.

PMID:
18684638
33.

ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.

Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A; Intergruppo Italiano Linfomi (IIL).

Ann Oncol. 2008 Apr;19(4):763-8. doi: 10.1093/annonc/mdm575. Epub 2008 Jan 6.

PMID:
18180244
34.

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.

Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA.

Leukemia. 2008 Mar;22(3):487-95. Epub 2007 Dec 20. Review.

PMID:
18094718
35.

Use of intrapleural bortezomib in myelomatous pleural effusion.

Iannitto E, Minardi V, Tripodo C.

Br J Haematol. 2007 Nov;139(4):621-2. No abstract available.

PMID:
17979947
36.

Rare HVR1-HCV genotype 1b variants in patients with B non Hodgkin's lymphoma. Comparison with viral sequences detected in cases of lymphoproliferative disorders and B cell compartmentalisation.

Dettori S, Argentini C, Marcucci F, Spada E, Chionne P, Candido A, Madonna E, Ciccaglione AR, Bianco E, Iannitto E, Musto P, Liso V, De Renzo A, Pagano L, Nieddu G, Pulsoni A, Mele A, Rapicetta M.

New Microbiol. 2007 Jul;30(3):265-70.

37.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.

PMID:
17646666
38.

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C.

Blood. 2007 Oct 1;110(7):2316-23. Epub 2007 Jun 20.

39.

Reply to Pich et al.: intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study.

Tripodo C, Florena AM, Iannitto E, Franco V.

Eur J Haematol. 2006 Oct;77(4):360; author reply 361. No abstract available.

40.

High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.

Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M.

Haematologica. 2006 Apr;91(4):554-7.

41.

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A.

Haematologica. 2006 Apr;91(4):475-81.

42.

NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.

Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G; Intergruppo Italiano Linfomi.

Ann Oncol. 2006 May;17(5):794-800. Epub 2006 Feb 23.

PMID:
16497823
43.

Splenic marginal zone lymphoma: a prognostic model for clinical use.

Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E; Integruppo Italiano Linfomi.

Blood. 2006 Jun 15;107(12):4643-9. Epub 2006 Feb 21.

44.

MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.

Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.

Clin Cancer Res. 2006 Jan 15;12(2):529-35.

45.

Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma.

Iannitto E, Minardi V, Callea V, Stelitano C, Calvaruso G, Tripodo C, Quintini G, De Cantis S, Ambrosetti A, Pizzolo G, Franco V, Florena AM, Abbadessa V.

Eur J Haematol. 2006 Feb;76(2):134-40.

PMID:
16405434
46.

Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement.

Florena AM, Tripodo C, Porcasi R, Ingrao S, Fadda MR, De Cantis S, Iannitto E, Franco V.

Leuk Lymphoma. 2006 Jan;47(1):49-57.

PMID:
16321827
47.

Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.

Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M.

Oncology. 2005;68(4-6):438-45. Epub 2005 Jul 14. Review.

PMID:
16020974
48.

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mulè A, Tripodo C, Quintini G, Abbadessa V.

Eur J Haematol. 2005 Aug;75(2):130-5.

PMID:
16000129
49.

Hepatitis B virus reactivation and alemtuzumab therapy.

Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxí A, Di Stefano R.

Eur J Haematol. 2005 Mar;74(3):254-8. Erratum in: Eur J Haematol. 2005 Aug;75(2):183. Trapani, Rosa D [corrected to Di Trapani, Rosa]; Stefano, Rosa D [corrected to Di Stefano, Rosa].

PMID:
15693796
50.

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment.

Iannitto E, Ammatuna E, Tripodo C, Marino C, Calvaruso G, Florena AM, Montalto G, Franco V.

Hematol J. 2004;5(6):530-3.

PMID:
15570298

Supplemental Content

Loading ...
Support Center